A Phase 3 interventional study of 5 mg BGM0504 injection and 10 mg BGM0504 injection administered subcutaneously (SC) once a week in Overweight or Obesity, sponsored by BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. (part of BrightGene Bio-Medical Technology Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing BGM0504 in Obesity — none open to participants now, none under way, none of them phase 3. BGM0504 · Obesity.
Among the 10 studies testing BGM0504 in Obesity, this one has the largest enrollment, is one of 3 that started in 2024, is the only one in phase 3, and was the 1st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →None of the 10 studies testing BGM0504 in Obesity is open now. The open studies under Obesity, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 3 started in 2024.
This study's enrollment of 652 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 78 across the 10 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd., one of the names counted as BrightGene Bio-Medical Technology Co., Ltd.. Under that name alone:
This is the only study on the registry with BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. as lead sponsor.
11 studies in Obesity by BrightGene Bio-Medical Technology Co., Ltd.: none open now, none under way, none of them phase 3. Of 11 finished, 0 (0%) have results posted.
Among the 11 studies in Obesity by BrightGene Bio-Medical Technology Co., Ltd., this one has the largest enrollment, is one of 2 that started in 2024, is the only one in phase 3, and was the 1st registered.
BrightGene Bio-Medical Technology Co., Ltd.’s Obesity studies by the year they started, since 2023.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing BGM0504 in Obesity, from their registry updates:
Among BrightGene Bio-Medical Technology Co., Ltd.’s 11 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled phase III validation clinical study in Chinese adult non-diabetic overweight or obese Participants. The main purpose is to evaluate the clinical efficacy of BGM0504 injection for 36 weeks of administration as an adjunct to diet, exercise, and behavioral interventions in overweight or obese non-diabetic adults in China for weight management, and to evaluate the clinical efficacy and safety of BGM0504 injection for 52 weeks of administration.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 652 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →This is the only study on the registry with BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. as lead sponsor.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 5 mg BGM0504 injection
Drug: 10 mg BGM0504 injection administered subcutaneously (SC) once a week
Drug: 15 mg BGM0504 injection
Drug: BGM0504 placebo
5mg BGM0504 injection administered subcutaneously (SC) once a week.
10mg BGM0504 injection administered subcutaneously (SC) once a week.
15mg BGM0504 injection administered subcutaneously (SC) once a week.
BGM0504 placebo administered SC once a week.
Percent Change from Baseline in Body Weight
Change from baseline in body weight after 36 weeks of treatment
Time frame: Baseline,Week 36
Percentage of Participants Who Achieve≥5% Body Weight Reduction
Percentage of Participants Who Achieve≥5% Body Weight Reduction
Time frame: Baseline,Week 36
Percent Change From Baseline in Body Weight
Percent Change from Baseline in Body Weight after 52weeks of treatment
Time frame: Baseline, Week 52
Change From Baseline in Body Weight
Change from baseline in body weight
Time frame: Baseline, Week36 and 52
Percentage of Participants Who Achieve≥5% Body Weight Reduction
Percentage of Participants Who Achieve≥5% Body Weight Reduction
Time frame: Baseline, Week 36 and 52
Percentage of Participants Who Achieve≥10% Body Weight Reduction
Percentage of Participants Who Achieve≥10% Body Weight Reduction
Time frame: Baseline, Week 36 and 52
Percentage of Participants Who Achieve≥15%Body Weight Reduction
Percentage of Participants Who Achieve≥15%Body Weight Reduction
Time frame: Baseline, Week 36 and 52
Percentage of Participants Who Achieve≥20% Body Weight Reduction
Percentage of Participants Who Achieve≥20% Body Weight Reduction.
Time frame: Baseline, Week 36 and 52
Change From Baseline in Waist Circumference
Change From Baseline in Waist Circumference after 52weeks of treatment.
Time frame: Baseline, Week 36 and 52
Change From Baseline in Body Mass Index (BMI)
Change From Baseline in Body Mass Index (BMI) after 52weeks of treatment
Time frame: Baseline, Week 36 and 52
Change From Baseline in Fasting Glucose
Change From Baseline in Fasting Glucose after 52weeks of treatment
Time frame: Baseline, Week 36 and 52
Change From Baseline in Hemoglobin A1c (HbA1c)
Change From Baseline in Hemoglobin A1c (HbA1c) after 52weeks of treatment.
Time frame: Baseline, Week 36 and 52
Ran from Oct 2024 to primary completion in Mar 2026, 16 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 16 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2025 → Mar 2026, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BGM0504